Plain-English translation of NCT04713657 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Babies born with conditions like Tetralogy of Fallot have hearts that don't grow new muscle cells the way healthy hearts do. This trial tests whether propranolol—a medication already approved for other uses in infants—can help restart the natural process of heart muscle growth. Researchers will give some babies the medication and others a placebo (inactive treatment) to see if it helps their hearts develop better before surgery.
Heart problems are common in babies with congenital heart disease, and they often develop heart failure later in life. There are currently no medications designed to help their heart muscle grow and heal. This study aims to see if this medication could offer a new way to prevent heart failure and improve long-term health.
You likely qualify if…
You likely don't qualify if…
If your baby is enrolled, you will give the medication (or placebo) at home by mouth four times a day, starting when your baby is about one month old and continuing until four months old or until 24 hours before their scheduled heart surgery, whichever comes first. You'll receive labeled syringes to make dosing easy and accurate based on your baby's weight. During surgery, the doctors will collect a small piece of heart tissue, which researchers will examine to see if new heart muscle cells have grown.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States